EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSDCDG00000003390
Gene Symbol: CACNA1A
3 Cross references
200 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSDCDG00000003259
Gene Symbol: CACNA1B
3 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSDCDG00000033432
Gene Symbol: CACNA1D
3 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSDCDG00000001393
Gene Symbol: CACNA1E
3 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 F

Ensembl ID : ENSDCDG00000003632
Gene Symbol: CACNA1F
3 Cross references
177 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 G

Ensembl ID : ENSDCDG00000001876
Gene Symbol: CACNA1G
3 Cross references
197 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSDCDG00000000418
Gene Symbol: CACNA1I
3 Cross references
191 Possible Orthologues:

Cannabinoid Receptor 1

Ensembl ID : ENSDCDG00000022944
Gene Symbol: CNR1
1 Cross references
153 Possible Orthologues:

Cannabinoid Receptor 2-Like

Ensembl ID : ENSDCDG00000002815
Gene Symbol: LOC114790961
3 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSDCDG00000023055
Gene Symbol: CA12
3 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSDCDG00000004486
Gene Symbol: CA14
3 Cross references
208 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSDCDG00000017905
Gene Symbol: LOC114792121
3 Cross references
200 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).